Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT06386588 Not yet recruiting - Schizophrenia Clinical Trials

The Effects of Auditory Stimulation During Sleep on Brain Networks in Schizophrenia

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

In this research study the investigators will use sleep headbands to measure brain rhythms and to improve their coordination across brain regions. The headbands will be worn at home for multiple nights. On some nights the headbands will play soft sounds at specific times during sleep. The investigators are interested in learning whether this timed auditory stimulation may be a strategy to improve the coordination of sleep rhythms across brain regions, improve network communication, and as a result, improve memory. The investigators will study 30 adults aged 18-45 with schizophrenia and 30 demographically matched healthy controls. Participants will first have a daytime MRI scan, during which they will complete a finger tapping motor sequence task (MST), followed by a week of sleep at home with a sleep headband. They will also do the MST at home on two of the nights. On the final day of the study, participants will return for a second MRI scan.

NCT ID: NCT06384521 Not yet recruiting - Schizophrenia Clinical Trials

Lifestyle MIND- Feasibility for Randomized Wait-list Control Trial

MIND
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to examine if it is feasible to randomly assign people into two groups and participate in Lifestyle MIND (Mental Illness and/N' Diabetes) at two different times. Lifestyle MIND is a diabetes lifestyle intervention recently developed for people with serious mental illness (SMI). It is known to be helpful for people with SMI who complete it, but the investigators do not know the effect in comparison to those who do not participate in it. The main questions it aims to answer are: - Does Lifestyle MIND improve diabetes control among people with SMI? - Will the effect of Lifestyle MIND be sustained 10 weeks after program completion? - From the provider's perspective, what are the barriers of achieving optimal diabetes treatment outcomes for patients with SMI? Researchers will compare outcomes of participants in the intervention with those in the wait-list control arm, to see if there will be significant differences in blood glucose level, compliance of diabetes self-management, time staying active, number of emergency department (ED) visits and psychiatric hospitalization, and subjective well-being.

NCT ID: NCT06376734 Not yet recruiting - Schizophrenia Clinical Trials

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Searchlight
Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

NCT ID: NCT06375902 Not yet recruiting - Clinical trials for Schizophrenia; Psychosis

The Fragility of Metaphors (FraMe): Learning, Loosing, and How to Train Them

FRAME
Start date: April 2024
Phase:
Study type: Observational

Tracking down the difficulties in metaphor comprehension experienced by individuals with schizophrenia across different metaphor types and exploring the neurological correlates via EEG recording technique

NCT ID: NCT06374290 Not yet recruiting - Smoking Cessation Clinical Trials

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.

NCT ID: NCT06372210 Completed - Schizophrenia Clinical Trials

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Start date: June 26, 2023
Phase: N/A
Study type: Interventional

The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.

NCT ID: NCT06370793 Active, not recruiting - Schizophrenia Clinical Trials

Ningbo Severe Mental Disorders Cohort

NEED
Start date: July 1, 2018
Phase:
Study type: Observational [Patient Registry]

In recent years, the prevalence of severe mental disorders in China has continued to grow, and the burden of disease in society has continued to rise. In order to improve the prognosis of patients with severe mental disorders and reduce the risk of disease relapse or readmission, researchers established a cohort based on the Ningbo Mental Health Information System in Ningbo, a sub-provincial city in the southern wing of the Yangtze River Delta of China, with a resident population of more than 9 million, and linked it to the residents' health records, and through the data linkage obtained data on patients in the full cycle of pre-diagnosis, diagnosis, follow-up, disease changes and death, realising full-cycle management of patients with severe mental disorders. Currently, NEED has accumulated data on more than 50,000 patients with severe mental disorders and obtained multi-dimensional longitudinal information through long-term follow-up and data linkage. All diseases follow the World Health Organization International Classification of Diseases 10th Edition (ICD-10) for clinical coding, and available data include baseline demographics, past history, family history, social functioning deficit screening scale scores, risk assessment, and so on and longitudinal health information from electronic health records (EHR), providing a solid data base for future real-world studies.

NCT ID: NCT06361667 Recruiting - Schizophrenia Clinical Trials

Culture and Well-being: Art as Prescription Therapy ("Art on Prescription")

AoP
Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Cluster randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL).

NCT ID: NCT06361407 Not yet recruiting - Schizophrenia Clinical Trials

Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia

SensoSchiz
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Disturbances in the sense of self and time could play an important role in the development of psychotic symptoms. Previous work has shown that patients have difficulty preparing to process information on the scale of a second, but are abnormally disturbed by slightly asynchronous information on the millisecond scale. In both cases, the anomalies could explain the patients' unusual experience of time. The hypothesis in neurotypical patients is that small delays or asynchronies asynchronies are treated as irrelevant information and ignored and ignored, whereas in patients suffering from schizophrenia they would disrupt the flow of time. This hypothesis is tested with a new visual illusion.

NCT ID: NCT06361160 Not yet recruiting - Clinical trials for Treatment Resistant Schizophrenia

Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation

HALLUSTIM
Start date: April 2024
Phase: N/A
Study type: Interventional

Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected individuals. One third of patients suffering from schizophrenia will evolve towards a resistant form of the disease, amongst which many will suffer from auditory-verbal hallucinations (AVH) that current therapeutic approaches struggle to alleviate. Previous work from our team has demonstrated the possibility of robustly inferring the periods of occurrence of AVH from fMRI data, paving the way for the development of a closed-loop neuromodulation system comprised of an electrode array positioned in Broca's area, which would detect AVH in real time, and effector electrodes which would stimulate the temporo-parietal cortex to interrupt them. The aim of this project is to assess the feasibility of this system. To do so, we will first test the ability of transcranial magnetic stimulation of the "continuous theta burst" (cTBS) type, applied at the time of AVH onset, to reduce their duration and intensity, and assess whether this is associated with therapeutic response to the current gold standard rTMS protocol for AVH reduction through neuroplasticity induction. Demonstrating the feasibility of acute suppression of AVH by cortical neurostimulation is an essential element in the feasibility of a closed-loop reactive neuromodulation system. The research project comprises two phases: -Phase 1: randomized controlled clinical trial (1 weekly session per patient over 12 weeks: 6 active stimulation sessions and 6 sham sessions) evaluating the phasic effects of rTMS on AVHs as they appear during the sessions. Phase 2: open-label study offering patients a routine rTMS protocol which has demonstrated its effects on AVH (10 TMS sessions over one workweek - twice daily with 1-hour intervals, MULTIMODHAL study, NCT01373866).